Multifocal epithelial tumors and field cancerization: Stroma as a primary determinant

Journal of Clinical Investigation

Volumn 124, Issue 4, 2014, Pages 1446-1453

  Dotto, G Paolo ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH; CARCINOGENESIS; EPITHELIUM CELL; EPITHELIUM TUMOR; HUMAN; INFLAMMATION; MESENCHYMAL STROMA CELL; METASTASIS; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; STROMA;

DISEASE PROGRESSION; EPIGENESIS, GENETIC; EPITHELIUM; FEMALE; FIBROBLASTS; HUMANS; INFLAMMATION; MALE; MESENCHYMAL STROMAL CELLS; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 84897489129     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72589     Document Type: Review

References (159)

1. Cardiff RD, Borowsky AD. Precancer: sequentially acquired or predetermined? Toxicol Pathol. 2010;38(1):171-179.
2. Gatenby R. Perspective: Finding cancer's first principles. Nature. 2012;491(7425):S55.
3. Eifert C, Powers RS. From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer. 2012;12(8):572-578.
4. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006;6(12):924-935. (Pubitemid 44862677)
5. Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL. Clinical implications and utility of field cancerization. Cancer Cell Int. 2007;7:2.
6. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6(5):963-968.
7. Rosso S, et al. Multiple tumours in survival estimates. Eur J Cancer. 2009;45(6):1080-1094.
8. Schottenfeld D. The epidemiology of multiple primary cancers. CA Cancer J Clin. 1977;27(4):233-240.
9. Weir HK, Johnson CJ, Thompson TD. The effect of multiple primary rules on population-based cancer survival. Cancer Causes Control. 2013;24(6):1231-1242.
10. Braisch U, Meyer M, Radespiel-Troger M. Risk of tobacco-related multiple primary cancers in Bavaria, Germany. BMC Cancer. 2012;12:250.
11. Bratslavsky G, Linehan WM. Long-term management of bilateral, multifocal, recurrent renal carcinoma. Nat Rev Urol. 2010;7(5):267-275.
12. Jain KS, Sikora AG, Baxi SS, Morris LG. Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer. Cancer. 2013;119(10):1832-1837.
13. Jain S, Rezo A, Shadbolt B, Dahlstrom JE. Synchronous multiple ipsilateral breast cancers: implications for patient management. Pathology. 2009;41(1):57-67.
14. Kuligina E, Reiner A, Imyanitov EN, Begg CB. Evaluating cancer epidemiologic risk factors using multiple primary malignancies. Epidemiology. 2010;21(3):366-372.
15. Levi F, et al. High constant incidence of second primary colorectal cancer. Int J Cancer. 2013;132(7):1679-1682.
16. Levi F, Randimbison L, Maspoli M, Te VC, La Vecchia C. High incidence of second basal cell skin cancers. Int J Cancer. 2006;119(6):1505-1507. (Pubitemid 44258833)
17. Levi F, Te VC, Randimbison L, Maspoli M, La Vecchia C. Second primary oral and pharyngeal cancers in subjects diagnosed with oral and pharyngeal cancer. Int J Cancer. 2006;119(11):2702-2704. (Pubitemid 44691328)
18. Albertsen PC. Commentary: occult prostate cancer - imposter or the real deal? Int J Epidemiol. 2007;36(2):281-282. (Pubitemid 47064326)
19. Khurana KK, Loosmann A, Numann PJ, Khan SA. Prophylactic mastectomy: pathologic findings in high-risk patients. Arch Pathol Lab Med. 2000;124(3):378-381. (Pubitemid 30152138)
20. Welch HG, Black WC. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med. 1997;127(11):1023-1028. (Pubitemid 27516615)
21. Zlotta AR, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst. 2013;105(14):1050-1058.
22. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9-22.
23. Hofbauer GF, Bavinck JN, Euvrard S. Organ transplantation and skin cancer: basic problems and new perspectives. Exp Dermatol. 2010;19(6):473-482.
24. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367-1380.
25. Ishizumi T, McWilliams A, MacAulay C, Gazdar A, Lam S. Natural history of bronchial preinvasive lesions. Cancer Metastasis Rev. 2010;29(1):5-14.
26. Lee P, et al. Color fluorescence ratio for detection of bronchial dysplasia and carcinoma in situ. Clin Cancer Res. 2009;15(14):4700-4705.
27. Heaphy CM, Griffith JK, Bisoffi M. Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Res Treat. 2009;118(2):229-239.
28. Huston TL, Simmons RM. Locally recurrent breast cancer after conservation therapy. Am J Surg. 2005;189(2):229-235. (Pubitemid 40255119)
29. Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol. 2010;41(6):781-793.
30. Trujillo KA, Jones AC, Griffith JK, Bisoffi M. Markers of field cancerization: proposed clinical applications in prostate biopsies. Prostate Cancer. 2012;2012:302894.
31. Hoffman RM. Clinical practice. Screening for prostate cancer. N Engl J Med. 2011;365(21):2013-2019.
32. Prevo LJ, Sanchez CA, Galipeau PC, Reid BJ. p53-mutant clones and field effects in Barrett's esophagus. Cancer Res. 1999;59(19):4784-4787. (Pubitemid 29472876)
33. Hyatt BJ, Paull PE, Wassef W. Gastric oncology: an update. Curr Opin Gastroenterol. 2009;25(6):570-578.
34. Damania D, et al. Nanocytology of rectal colonocytes to assess risk of colon cancer based on field cancerization. Cancer Res. 2012;72(11):2720-2727.
35. Hoglund M. Bladder cancer, a two phased disease? Semin Cancer Biol. 2007;17(3):225-232. (Pubitemid 46413074)
36. Rosenthal AN, Ryan A, Hopster D, Jacobs IJ. Molecular evidence of a common clonal origin and subsequent divergent clonal evolution in vulval intraepithelial neoplasia, vulval squamous cell carcinoma and lymph node metastases. Int J Cancer. 2002;99(4):549-554. (Pubitemid 34461607)
37. Bastian BC. Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene. 2003;22(20):3081-3086. (Pubitemid 36713759)
38. Giannopoulos S, Kyritsis AP. Diagnosis and management of multifocal gliomas. Oncology. 2010;79(3-4):306-312.
39. Brodsky RA, Jones RJ. Riddle: what do aplastic anemia, acute promyelocytic leukemia, and chronic myeloid leukemia have in common? Leukemia. 2004;18(10):1740-1742. (Pubitemid 39386359)
40. Scadden DT. Rethinking stroma: lessons from the blood. Cell Stem Cell. 2012;10(6):648-649.
41. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63(8):1727-1730. (Pubitemid 36460827)
42. Jonason AS, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci U S A. 1996;93(24):14025-14029. (Pubitemid 26424239)
43. van Houten VM, et al. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol. 2002;198(4):476-486. (Pubitemid 35447001)
44. Waridel F, et al. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene. 1997;14(2):163-169. (Pubitemid 27068302)
45. Chung GT, Sundaresan V, Hasleton P, Rudd R, Taylor R, Rabbitts PH. Clonal evolution of lung tumors. Cancer Res. 1996;56(7):1609-1614. (Pubitemid 26104025)
46. Sundaresan V, et al. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene. 1992;7(10):1989-1997.
47. Barrett MT, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet. 1999;22(1):106-109. (Pubitemid 29214816)
48. Crum CP, McKeon FD. p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol. 2010;5:349-371.
49. Ferone G, et al. p63 control of desmosome gene expression and adhesion is compromised in AEC syndrome. Hum Mol Genet. 2013;22(3):531-543.
50. Koster MI, Roop DR. Sorting out the p63 signaling network. J Invest Dermatol. 2008;128(7):1617-1619. (Pubitemid 351847389)
51. Escher A, Piotet E, Waridel F, Iggo R, Monnier P. p53 Mutation in histologically normal mucosa of the aero-digestive tract is not a marker of increased risk for second primary carcinoma in head and neck cancer patients. Eur Arch Otorhinolaryngol. 2009;266(4):547-551.
52. Chung KY, et al. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res. 1993;53(7):1676-1683. (Pubitemid 23113251)
53. Grepmeier U, et al. Deletions at chromosome 2q and 12p are early and frequent molecular alterations in bronchial epithelium and NSCLC of long-term smokers. Int J Oncol. 2005;27(2):481-488.
54. Gonzalez-Moles MA, Scully C, Ruiz-Avila I. Molecular findings in oral premalignant fields: update on their diagnostic and clinical implications. Oral Dis. 2012;18(1):40-47.
55. Abyzov A, et al. Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells. Nature. 2012;492(7429):438-442.
56. Dworkin AM, Huang TH, Toland AE. Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol. 2009;19(3):165-171.
57. Guo M, et al. Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res. 2004;10(15):5131-5136. (Pubitemid 39099787)
58. Ushijima T. Epigenetic field for cancerization. J Biochem Mol Biol. 2007;40(2):142-150. (Pubitemid 46515191)
59. Ramachandran K, Singal R. DNA methylation and field cancerization. Epigenomics. 2012;4(3):243-245.
60. Asada K, et al. FHL1 on chromosome X is a single-hit gastrointestinal tumor-suppressor gene and contributes to the formation of an epigenetic field defect. Oncogene. 2013;32(17):2140-2149.
61. Ando T, et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer. 2009;124(10):2367-2374.
62. Suzuki H, et al. Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis. 2010;31(12):2066-2073.
63. Arai E, Kanai Y, Ushijima S, Fujimoto H, Mukai K, Hirohashi S. Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int J Cancer. 2006;119(2):288-296.
64. Kar S, et al. An insight into the various regulatory mechanisms modulating human DNA methyltransferase 1 stability and function. Epigenetics. 2012;7(9):994-1007.
65. O'Hagan HM, et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG islands. Cancer Cell. 2011;20(5):606-619.
66. Takeshima H, Ikegami D, Wakabayashi M, Niwa T, Kim YJ, Ushijima T. Induction of aberrant trimethylation of histone H3 lysine 27 by inflammation in mouse colonic epithelial cells. Carcinogenesis. 2012;33(12):2384-2390.
67. Chai H, Brown RE. Field effect in cancer-an update. Ann Clin Lab Sci. 2009;39(4):331-337.
68. Heaphy CM, et al. Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer. 2006;119(1):108-116.
69. Hittelman WN. Genetic instability in epithelial tissues at risk for cancer. Ann N Y Acad Sci. 2001;952:1-12. (Pubitemid 34060005)
70. Shin DM, et al. p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev. 2001;10(6):603-609. (Pubitemid 32703194)
71. Stoler DL, et al. Genomic instability in invasive breast carcinoma measured by inter-simple sequence repeat PCR. Breast Cancer Res Treat. 2006;97(1):107-110.
72. Stoler DL, et al. Comparative genomic instabilities of thyroid and colon cancers. Arch Otolaryngol Head Neck Surg. 2007;133(5):457-463. (Pubitemid 46799781)
73. Wiseman SM, Stoler DL, Anderson GR. The role of genomic instability in the pathogenesis of squamous cell carcinoma of the head and neck. Surg Oncol Clin N Am. 2004;13(1):1-11. (Pubitemid 38328490)
74. Ha PK, et al. Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clin Cancer Res. 2002;8(7):2260-2265. (Pubitemid 34753599)
75. Tulah AS, Birch-Machin MA. Stressed out mitochondria: The role of mitochondria in ageing and cancer focussing on strategies and opportunities in human skin. Mitochondrion. 2013;13(5):444-453.
76. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194-1217.
77. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-545. (Pubitemid 32173595)
78. Cantisani C, et al. Actinic keratosis: review of the literature and new patents. Recent Pat Inflamm Allergy Drug Discov. 2013;7(2):168-175.
79. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899.
80. Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. 2012;22(1):33-40.
81. Mueller MM. Inflammation in epithelial skin tumours: old stories and new ideas. Eur J Cancer. 2006;42(6):735-744.
82. Murphy JE, Morales RE, Scott J, Kupper TS. IL-1α, innate immunity, and skin carcinogenesis: the effect of constitutive expression of IL-1α in epidermis on chemical carcinogenesis. J Immunol. 2003;170(11):5697-5703. (Pubitemid 36617862)
83. Lao HC, Akunda JK, Chun KS, Flake GP, Yuspa SH, Langenbach R. Genetic ablation of cyclooxygenase-2 in keratinocytes produces a cell-autonomous defect in tumor formation. Carcinogenesis. 2012;33(11):2293-2300.
84. Muller-Decker K. Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence. Cancer Metastasis Rev. 2011;30(3-4):343-361.
85. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenberger G. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci U S A. 2002;99(19):12483-12488.
86. Cooks T, et al. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer cell. 2013;23(5):634-646.
87. Grivennikov S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15(2):103-113.
88. Seril DN, Liao J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis. 2003;24(3):353-362. (Pubitemid 36432628)
89. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101-2114.e5.
90. Wroblewski LE, Peek RM, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010;23(4):713-739.
91. Tu S, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell. 2008;14(5):408-419.
92. Bachelor MA, Bowden GT. UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression. Semin Cancer Biol. 2004;14(2):131-138. (Pubitemid 38234755)
93. Yaar M, Gilchrest BA. Photoageing: mechanism, prevention and therapy. Br J Dermatol. 2007;157(5):874-887. (Pubitemid 47583483)
94. Hu B, et al. Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell. 2012;149(6):1207-1220.
95. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306(7):737-745.
96. Reynolds P. Smoking and breast cancer. J Mammary Gland Biol Neoplasia. 2013;18(1):15-23.
97. Salem AF, et al. Cigarette smoke metabolically promotes cancer, via autophagy and premature aging in the host stromal microenvironment. Cell Cycle. 2013;12(5):818-825.
98. Yoshimoto S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499(7456):97-101.
99. Campisi J, Andersen JK, Kapahi P, Melov S. Cellular senescence: a link between cancer and age-related degenerative disease? Semin Cancer Biol. 2011;21(6):354-359.
100. Kuilman T, Peeper DS. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer. 2009;9(2):81-94.
101. Kuilman T, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008;133(6):1019-1031. (Pubitemid 351787746)
102. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346-354.
103. Hoenicke L, Zender L. Immune surveillance of senescent cells - biological significance in cancer- and non-cancer pathologies. Carcinogenesis. 2012;33(6):1123-1126.
104. Kang TW, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011;479(7374):547-551.
105. Xue W, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656-660. (Pubitemid 46232886)
106. Bechtel W, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med. 2010;16(5):544-550.
107. Hu M, Polyak K. Microenvironmental regulation of cancer development. Curr Opin Genet Dev. 2008;18(1):27-34. (Pubitemid 351694443)
108. Hu M, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet. 2005;37(8):899-905. (Pubitemid 41077119)
109. Jiang L, et al. Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Res. 2008;68(23):9900-9908.
110. Weinberg RA. Coevolution in the tumor microenvironment. Nat Genet. 2008;40(5):494-495. (Pubitemid 351601230)
111. Bar J, Moskovits N, Oren M. Involvement of stromal p53 in tumor-stroma interactions. Semin Cell Dev Biol. 2010;21(1):47-54.
112. Fukino K, Shen L, Matsumoto S, Morrison CD, Mutter GL, Eng C. Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets. Cancer Res. 2004;64(20):7231-7236. (Pubitemid 39372057)
113. Hill R, Song Y, Cardiff RD, Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell. 2005;123(6):1001-1011. (Pubitemid 41785416)
114. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet. 2002;32(3):355-357. (Pubitemid 35266108)
115. Matsumoto N, Yoshida T, Yamashita K, Numata Y, Okayasu I. Possible alternative carcinogenesis pathway featuring microsatellite instability in colorectal cancer stroma. Br J Cancer. 2003;89(4):707-712. (Pubitemid 37076178)
116. Paterson RF, et al. Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma. Cancer. 2003;98(9):1830-1836. (Pubitemid 37310224)
117. Tuhkanen H, et al. Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p. Int J Cancer. 2004;109(2):247-252. (Pubitemid 38240927)
118. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392-401.
119. Driskell RR, et al. Distinct fibroblast lineages determine dermal architecture in skin development and repair. Nature. 2013;504(7479):277-281.
120. Koumas L, King AE, Critchley HO, Kelly RW, Phipps RP. Fibroblast heterogeneity: existence of functionally distinct Thy 1(+) and Thy 1(-) human female reproductive tract fibroblasts. Am J Pathol. 2001;159(3):925-935. (Pubitemid 32847183)
121. Koumas L, Smith TJ, Feldon S, Blumberg N, Phipps RP. Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am J Pathol. 2003;163(4):1291-1300. (Pubitemid 37175078)
122. Phipps RP, et al. Characterization of two major populations of lung fibroblasts: distinguishing morphology and discordant display of Thy 1 and class II MHC. Am J Respir Cell Mol Biol. 1989;1(1):65-74.
123. Sorrell JM, Baber MA, Caplan AI. Site-matched papillary and reticular human dermal fibroblasts differ in their release of specific growth factors/cytokines and in their interaction with keratinocytes. J Cell Physiol. 2004;200(1):134-145. (Pubitemid 38720629)
124. Chang HY, et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A. 2002;99(20):12877-12882.
125. Rinn JL, Bondre C, Gladstone HB, Brown PO, Chang HY. Anatomic demarcation by positional variation in fibroblast gene expression programs. PLoS Genet. 2006;2(7):e119.
126. Rinn JL, et al. A dermal HOX transcriptional program regulates site-specific epidermal fate. Genes Dev. 2008;22(3):303-307. (Pubitemid 351214272)
127. Sorrell JM, Baber MA, Caplan AI. Clonal characterization of fibroblasts in the superficial layer of the adult human dermis. Cell Tissue Res. 2007;327(3):499-510. (Pubitemid 46232320)
128. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science. 1998;280(5366):1036-1037. (Pubitemid 28234937)
129. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer. 2003;107(1):1-10. (Pubitemid 37100079)
130. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 2007;21(20):2525-2538. (Pubitemid 47607664)
131. Hemminki A, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 1998;391(6663):184-187. (Pubitemid 28092478)
132. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9(8):563-575.
133. Miyoshi H, Nakau M, Ishikawa TO, Seldin MF, Oshima M, Taketo MM. Gastrointestinal hamartomatous polyposis in Lkb1 heterozygous knockout mice. Cancer Res. 2002;62(8):2261-2266. (Pubitemid 34411702)
134. Katajisto P, et al. LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis. Nat Genet. 2008;40(4):455-459. (Pubitemid 351450888)
135. Vaahtomeri K, et al. Lkb1 is required for TGFβ-mediated myofibroblast differentiation. J Cell Sci. 2008;121(pt 21):3531-3540.
136. Hinz B, et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012;180(4):1340-1355.
137. Bhowmick NA, et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 2004;303(5659):848-851. (Pubitemid 38174665)
138. Placencio VR, et al. Stromal transforming growth factor-β signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. Cancer Res. 2008;68(12):4709-4718.
139. Li X, et al. Prostate tumor progression is mediated by a paracrine TGF-β/Wnt3a signaling axis. Oncogene. 2008;27(56):7118-7130.
140. Achyut BR, et al. Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling. PLoS Genet. 2013;9(2):e1003251.
141. Furusawa C, Kaneko K. A dynamical-systems view of stem cell biology. Science. 2012;338(6104):215-217.
142. Kicheva A, Cohen M, Briscoe J. Developmental pattern formation: insights from physics and biology. Science. 2012;338(6104):210-212.
143. Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol. 2009;10(7):445-457.
144. Potter JD. Morphogens, morphostats, microarchitecture and malignancy. Nat Rev Cancer. 2007;7(6):464-474. (Pubitemid 46809167)
145. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137(2):216-233.
146. Demehri S, Turkoz A, Kopan R. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell. 2009;16(1):55-66.
147. Dotto GP. Notch tumor suppressor function. Oncogene. 2008;27(38):5115- 5123.
148. Hu B, et al. Control of hair follicle cell fate by underlying mesenchyme through a CSL-Wnt5a-FoxN1 regulatory axis. Genes Dev. 2010;24(14):1519-1532.
149. Angel P, Szabowski A, Schorpp-Kistner M. Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene. 2001;20(19):2413-2423. (Pubitemid 32531299)
150. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003;3(11):859-868. (Pubitemid 37383716)
151. Rittie L, Fisher GJ. UV-light-induced signal cascades and skin aging. Ageing Res Rev. 2002;1(4):705-720. (Pubitemid 38344146)
152. Castel D, Mourikis P, Bartels SJ, Brinkman AB, Tajbakhsh S, Stunnenberg HG. Dynamic binding of RBPJ is determined by Notch signaling status. Genes Dev. 2013;27(9):1059-1071.
153. Johnson JE, Macdonald RJ. Notch-independent functions of CSL. Curr Top Dev Biol. 2011;97:55-74.
154. Marsh T, Pietras K, McAllister SS. Fibroblasts as architects of cancer pathogenesis. Biochim Biophys Acta. 2013;1832(7):1070-1078.
155. Polanska UM, Orimo A. Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol. 2013;228(8):1651-1657.
156. Goruppi S, Dotto GP. Mesenchymal stroma: primary determinant and therapeutic target for epithelial cancer. Trends Cell Biol. 2013;23(12):593-602.
157. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579-591. (Pubitemid 39025053)
158. Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found Symp. 2004;262:247-260.
159. Schmitt AR, Bordeaux JS. Solar keratoses: Photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies. Clin Dermatol. 2013;31(6):712-717.